From basic to clinical research in gastroenteropancreatic neuroendocrine tumor disease - The clinician-scientist perspective

Neuroendocrinology

Volumn 80, Issue SUPPL. 1, 2004, Pages 94-98

  Wiedenmann, Bertram ^a   Pape, Ulrich Frank ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Basic and clinical research; Neuroendocrine tumor; New drugs; Unresolved clinical issues

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CILENGITIDE; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; DOXORUBICIN; ETOPOSIDE; FLAVOPYRIDOL; FLUOROURACIL; GEFITINIB; MONOCLONAL ANTIBODY LM 609; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTHER; OCTREOTIDE; OXALIPLATIN; PACLITAXEL; RADIOISOTOPE; RAPAMYCIN; SNX 482; STREPTOZOCIN; UNCLASSIFIED DRUG; YTTRIUM 90;

CANCER GENETICS; CANCER INCIDENCE; CANCER RESEARCH; CATHETER ABLATION; CLINICAL TRIAL; CONFERENCE PAPER; CORRELATION ANALYSIS; DIAGNOSTIC TEST; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; DUODENUM CANCER; HORMONE RELEASE; HUMAN; INTESTINE CANCER; METASTASIS; MOLECULAR BIOLOGY; MOLECULAR MECHANICS; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ISLET CELL CARCINOMA; PHYSICIAN; PRIORITY JOURNAL; RADIORECEPTOR ASSAY; SIGNAL TRANSDUCTION; STOMACH CANCER; SURGICAL TECHNIQUE; TUMOR LOCALIZATION;

BIOMEDICAL RESEARCH; GASTROINTESTINAL NEOPLASMS; GROWTH SUBSTANCES; HUMANS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; RECEPTORS, GROWTH FACTOR;

EID: 6044249070     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000080749     Document Type: Conference Paper

References (41)

1. Modlin IM, Lye KD, Kidd M: A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97:934-959.
2. Rindi G, Bordi C: Highlights of the biology of endocrine tumours of the gut and pancreas. Endocr Relat Cancer 2003;10:427-436.
3. Kloppel G, Perren A, Heitz PU: The gastroenteropancreatic neuroendocrine cell system and its tumors: The WHO classification. Ann N Y Acad Sci 2004;1014:13-27.
4. Wiedenmann B, John M, Ahnert-Hilger G, Riecken EO: Molecular and cell biological aspects of neuroendocrine tumors of the gastroenteropancreatic system. J Mol Med 1998;76:637-647.
5. Caplin ME, Buscombe JR, Hilson AJ, Jones AL, Watkinson AF, Burroughs AK: Carcinoid tumour. Lancet 1998;352:799-805.
6. Federspiel BH, Burke AP, Sobin LH, Shekitka KM: Rectal and colonic carcinoids. A clinicopathologic study of 84 cases. Cancer 1990;65:135-140.
7. Bernick PE, Klimstra DS, Shia J, Minsky B, Saltz L, Shi W, Thaler H, Guillem J, Paty P, Cohen AM, Wong WD: Neuroendocrine carcinomas of the colon and rectum. Dis Colon Rectum 2004;47:163-169.
8. Lamberts SW, Hofland LJ, Nobels FR: Neuroendocrine tumor markers. Front Neuroendocrinol 2001;22:309-339.
9. Polak JM, Bloom SR, Adrian TE, Heitz P, Bryant MG, Pearse AG: Pancreatic polypeptide in insulinomas, gastrinomas, vipomas, and glucagonomas. Lancet 1976;i:328-330.
10. Pape UF, Bohmig M, Berndt U, Tiling N, Wiedenmann B, Plockinger U: Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a German referral center. Ann N Y Acad Sci 2004;1014:222-233.
11. Wiedenmann B, Jensen RT, Mignon M, Modlin CI, Skogseid B, Doherty G, Oberg K: Preoperative diagnosis and surgical management of neuroendocrine gastroenteropancreatic tumors: General recommendations by a consensus workshop. World J Surg 1998;22:309-318.
12. Lemmens I, Van de Ven WJ, Kas K, Zhang CX, Giraud S, Wautot V, Buisson N, De Witte K, Salandre J, Lenoir G, Pugeat M, Calender A, Parente F, Quincey D, Gaudray P, De Wit MJ, Lips CJ, Hoppener JW, Khodaei S, Grant AL, Weber G, Kytola S, Teh BT, Farnebo F, Thakker RV: Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1. Hum Mol Genet 1997;6:1177-1183.
13. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA, Crabtree JS, Wang Y, Roe BA, Weisemann J, Boguski MS, Agarwal SK, Kester MB, Kim YS, Heppner C, Dong Q, Spiegel AM, Burns AL, Marx SJ: Positional cloning of the gene for multiple endocrine neoplasia type 1. Science 1997;276:404-407.
14. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJ, Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells SA Jr, Marx SJ: Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86:5658-5671.
15. Ricke J, Klose KJ, Mignon M, Oberg K, Wiedenmann B: Standardisation of imaging in neuroendocrine tumours: Results of a European delphi process. Eur J Radiol 2001;37:8-17.
16. Zimmer T, Stolzel U, Bader M, Koppenhagen K, Hamm B, Buhr H, Riecken EO, Wiedenmann B: Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas. Gut 1996;39:562-568.
17. Breeman WA, de Jong M, Kwekkeboom DJ, Valkema R, Bakker WH, Kooij PP, Visser TJ, Krenning EP: Somatostatin receptor-mediated imaging and therapy: Basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 2001;28:1421-1429.
18. Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR: Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 1998;351:417-418.
19. Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJ, Kooij PP, de Herder WW, Feelders RA, van Eijck CH, de Jong M, Srinivasan A, Erion JL, Krenning EP: Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate. Eur J Nucl Med Mol Imaging 2003;30:417-422.
20. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D: Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992;326:519-523.
21. Moertel CG, Kvols LK, O'Connell MJ, Rubin J: Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991;68:227-232.
22. Rougier P, Mitry E: Chemotherapy in the treatment of neuroendocrine malignant tumors. Digestion 2000;62(suppl 1):73-78.
23. von Marschall Z, Scholz A, Cramer T, Schafer G, Schirner M, Oberg K, Wiedenmann B, Hocker M, Rosewicz S: Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 2003;95:437-448.
24. Wimmel A, Wiedenmann B, Rosewicz S: Autocrine growth inhibition by transforming growth factor beta-1 (TGFbeta-1) in human neuroendocrine tumour cells. Gut 2003;52:1308-1316.
25. Folkman J: Fundamental concepts of the angiogenic process. Curr Mol Med 2003;3:643-651.
26. Chaudhry A, Papanicolaou V, Oberg K, Heldin CH, Funa K: Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system. Cancer Res 1992;52:1006-1012.
27. Chaudhry A, Funa K, Oberg K: Expression of growth factor peptides and their receptors in neuroendocrine tumors of the digestive system. Acta Oncol 1993;32:107-114.
28. Nilsson O, Wangberg B, Kolby L, Schultz GS, Ahlman H: Expression of transforming growth factor alpha and its receptor in human neuroendocrine tumours. Int J Cancer 1995;60:645-651.
29. Shimizu T, Tanaka S, Haruma K, Kitadai Y, Yoshihara M, Sumii K, Kajiyama G, Shimamoto F: Growth characteristics of rectal carcinoid tumors. Oncology 2000;59:229-237.
30. Peghini PL, Iwamoto M, Raffeld M, Chen YJ, Goebel SU, Serrano J, Jensen RT: Overexpression of epidermal growth factor and hepatocyte growth factor receptors in a proportion of gastrinomas correlates with aggressive growth and lower curability. Clin Cancer Res 2002;8:2273-2285.
31. Wulbrand U, Remmert G, Zofel P, Wied M, Arnold R, Fehmann HC: mRNA expression patterns of insulin-like growth factor system components in human neuroendocrine tumours. Eur J Clin Invest 2000;30:729-739.
32. von Wichert G, Jehle PM, Hoeflich A, Koschnick S, Dralle H, Wolf E, Wiedenmann B, Boehm BO, Adler G, Seufferlein T: Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res 2000;60:4573-4581.
33. Krenning EP, Valkema R, Kooij PP, Breeman WA, Bakker WH, de Herder WW, van Eijck CH, Kwekkeboom DJ, de Jong M, Jamar F, Pauwels S: The role of radioactive somatostatin and its analogues in the control of tumor growth. Recent Results Cancer Res 2000;153:1-13.
34. Schmid HA, Schoeffter P: Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 2004;80(suppl 1):47-50.
35. Detjen KM, Welzel M, Farwig K, Brembeck FH, Kaiser A, Riecken EO, Wiedenmann B, Rosewicz S: Molecular mechanism of interferon-alfa-mediated growth inhibition in human neuroendocrine tumor cells. Gastroenterology 2000;118:735-748.
36. Detjen KM, Kehrberger JP, Drost A, Rabien A, Welzel M, Wiedenmann B, Rosewicz S: Interferon-gamma inhibits growth of human neuroendocrine carcinoma cells via induction of apoptosis. Int J Oncol 2002;21:1133-1140.
37. Faiss S, Pape UF, Bohmig M, Dorffel Y, Mansmann U, Golder W, Riecken EO, Wiedenmann B; International Lanreotide and Interferon Alfa Study Group: Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon-alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors. J Clin Oncol 2003;21:2689-2696.
38. Pape UF, Wiedenmann B: Adding interferonalpha to octreotide slows tumour progression compared with octreotide alone but evidence is lacking for improved survival in people with disseminated midgut carcinoid tumours. Cancer Treat Rev 2003;29:565-569.
39. 2+ channel activity is associated with chromogranin A secretion in human neuroendocrine tumor BON cells. J Membr Biol 2003;194:177-186.
40. 2+ channel properties in neuroendocrine tumor cell cultures investigated by whole-cell patch-clamp technique. Ann N Y Acad Sci 2004;1014:137-139.
41. Detjen KM, Welzel M, Wiedenmann B, Rosewicz S: Nonsteroidal anti-inflammatory drugs inhibit growth of human neuroendocrine tumor cells via G1 cell-cycle arrest. Int J Cancer 2003;107:844-853.